Amalus Therapeutics' objective is to significantly improve the lives of those suffering from cancer and fibrotic disorders
Amalus Therapeutics has raised $542K in total funding. The most recent round was Convertible Note. The last funding was announced in August 2023.
Amalus Therapeutics's investors include BioInnovation Institute.
Amalus Therapeutics is headquartered in Ghent, Belgium.
Amalus Therapeutics' objective is to significantly improve the lives of those suffering from cancer and fibrotic disorders
Amalus Therapeutics is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amalus Therapeutics — Funding & Investors." VCBacked, August 31, 2023, https://www.vcbacked.co/company/amalus-therapeutics. Accessed October 6, 2026.
VCBacked. (2023). Amalus Therapeutics — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/amalus-therapeutics
{{cite web |title=Amalus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amalus-therapeutics |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated